| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
A246710 Stock Overview
T&R Biofab Co., Ltd. engages in the research and development of medical devices for transplantation and tissue regeneration in the areas of orthopedics, plastic surgery, and dentistry.
T&R Biofab Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩20,100.00 |
| 52 Week High | ₩45,500.00 |
| 52 Week Low | ₩13,950.00 |
| Beta | 0.73 |
| 1 Month Change | -23.28% |
| 3 Month Change | 10.74% |
| 1 Year Change | 5.93% |
| 3 Year Change | 97.06% |
| 5 Year Change | n/a |
| Change since IPO | 221.60% |
Recent News & Updates
Do Insiders Own Lots Of Shares In T&R Biofab Co., Ltd. (KOSDAQ:246710)?
A look at the shareholders of T&R Biofab Co., Ltd. ( KOSDAQ:246710 ) can tell us which group is most powerful. Large...
Can You Imagine How T&R Biofab's (KOSDAQ:246710) Shareholders Feel About The 65% Share Price Increase?
T&R Biofab Co., Ltd. ( KOSDAQ:246710 ) shareholders might be concerned after seeing the share price drop 12% in the...
Do Institutions Own T&R Biofab Co., Ltd. (KOSDAQ:246710) Shares?
The big shareholder groups in T&R Biofab Co., Ltd. (KOSDAQ:246710) have power over the company. Generally speaking, as...
Shareholder Returns
| A246710 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | 2.0% | 1.3% | 0.9% |
| 1Y | 5.9% | -5.8% | -15.0% |
Return vs Industry: A246710 exceeded the KR Medical Equipment industry which returned -6.2% over the past year.
Return vs Market: A246710 exceeded the KR Market which returned -15.8% over the past year.
Price Volatility
| A246710 volatility | |
|---|---|
| A246710 Average Weekly Movement | 10.2% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 10.3% |
| 10% least volatile stocks in KR Market | 3.2% |
Stable Share Price: A246710 is more volatile than 75% of KR stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: A246710's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Wonsoo Yun | https://www.tnrbiofab.com |
T&R Biofab Co., Ltd. engages in the research and development of medical devices for transplantation and tissue regeneration in the areas of orthopedics, plastic surgery, and dentistry. It offers craniomaxillofacial meshes, dental meshes, and patient specific implants; and bioinks for 3D bioprinting and cell culture, stem cell research and delivery, and coating of scaffold and cultural dishes. The company was founded in 2013 and is based in Siheung-si, South Korea.
T&R Biofab Fundamentals Summary
| A246710 fundamental statistics | |
|---|---|
| Market Cap | ₩417.92b |
| Earnings (TTM) | -₩11.08b |
| Revenue (TTM) | ₩3.23b |
129.2x
P/S Ratio-37.7x
P/E RatioIs A246710 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A246710 income statement (TTM) | |
|---|---|
| Revenue | ₩3.23b |
| Cost of Revenue | ₩3.47b |
| Gross Profit | -₩234.30m |
| Other Expenses | ₩10.85b |
| Earnings | -₩11.08b |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -533.05 |
| Gross Margin | -7.24% |
| Net Profit Margin | -342.64% |
| Debt/Equity Ratio | 69.9% |
How did A246710 perform over the long term?
See historical performance and comparisonValuation
Is T&R Biofab undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
10.05x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate A246710's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A246710's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: A246710 is unprofitable, so we can't compare its PE Ratio to the KR Medical Equipment industry average.
PE vs Market: A246710 is unprofitable, so we can't compare its PE Ratio to the KR market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate A246710's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: A246710 is overvalued based on its PB Ratio (10x) compared to the KR Medical Equipment industry average (2.4x).
Future Growth
How is T&R Biofab forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
4.6%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as T&R Biofab has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has T&R Biofab performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-20.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A246710 is currently unprofitable.
Growing Profit Margin: A246710 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: A246710 is unprofitable, and losses have increased over the past 5 years at a rate of 20.6% per year.
Accelerating Growth: Unable to compare A246710's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A246710 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (30.5%).
Return on Equity
High ROE: A246710 has a negative Return on Equity (-26.58%), as it is currently unprofitable.
Financial Health
How is T&R Biofab's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: A246710's short term assets (₩63.7B) exceed its short term liabilities (₩1.7B).
Long Term Liabilities: A246710's short term assets (₩63.7B) exceed its long term liabilities (₩38.9B).
Debt to Equity History and Analysis
Debt Level: A246710 has more cash than its total debt.
Reducing Debt: A246710's debt to equity ratio has increased from 2.3% to 69.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A246710 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A246710 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 22.6% each year
Dividend
What is T&R Biofab current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A246710's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A246710's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A246710's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A246710's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A246710 has not reported any payouts.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Wonsoo Yun
no data
Tenure
Wonsoo Yun is Chief Executive Officer and President of T&R Biofab Co., Ltd.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.7%.
Top Shareholders
Company Information
T&R Biofab Co., Ltd.'s employee growth, exchange listings and data sources
Key Information
- Name: T&R Biofab Co., Ltd.
- Ticker: A246710
- Exchange: KOSDAQ
- Founded: 2013
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: ₩417.918b
- Shares outstanding: 20.79m
- Website: https://www.tnrbiofab.com
Location
- T&R Biofab Co., Ltd.
- #542, Smart-Hub Ind-Uni Convergence Ctr
- 237 Sangidaehak-ro
- Siheung-Si
- Gyeonggi-do
- 15073
- South Korea
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/17 00:00 |
| End of Day Share Price | 2022/05/17 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.